Aravive, Inc. (ARAV)

Market Cap	24.94M
Revenue (ttm)	6.10M
Net Income (ttm)	-55.58M
Shares Out	30.52M
EPS (ttm)	-2.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	105,752
Open	0.885
Previous Close	0.875
Day's Range	0.797 - 0.885
52-Week Range	0.580 - 4.250
Beta	2.42
Analysts	Buy
Price Target	18.56 (+2,171.2%)
Earnings Date	Oct 26, 2022

About ARAV

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a solub...

• Industry: Biotechnology
• IPO Date: Mar 21, 2014
• CEO: Gail McIntyre
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: ARAV

Full Company Profile

Financial Performance

In 2021, Aravive's revenue was $7.44 million, an increase of 30.91% compared to the previous year's $5.69 million. Losses were -$39.15 million, 28.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for ARAV stock is "Buy." The 12-month stock price forecast is 18.56, which is an increase of 2,171.17% from the latest price.

Price Target

$18.56

(2,171.17% upside)

Analyst Consensus: Buy

Stock Forecasts